Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic value of para-aortic lymph node dissection in gastric cancer with extensive lymph node metastasis: integrated analysis of three phase II trials (JCOG2212A).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Risk Factors for Body Weight Loss After Gastrectomy for Gastric Cancer Analyzed From the JCOG1001 Phase III Trial.

Annals of gastroenterological surgery·2026
Same author

Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan.

Global health & medicine·2025
Same author

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

The lancet. Gastroenterology & hepatology·2024
Same author

Histopathologic response in patients with curative resection with D2 dissection following neoadjuvant treatment for locally advanced gastric and esophagogastric junction adenocarcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same author

Prognostic Impact of Post-operative Infectious Complications in Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy: Post Hoc Analysis of a Randomized Controlled Trial, JCOG0501.

Journal of gastrointestinal cancer·2024
Same journal

Positive peritoneal cytology and recurrence patterns in endometrial cancer according to postoperative recurrence risk classification: a retrospective cohort study.

International journal of clinical oncology·2026
Same journal

Relationship between CCM3 expression and angiogenesis in esophageal squamous cell carcinoma and its possible mechanism.

International journal of clinical oncology·2026
Same journal

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

International journal of clinical oncology·2026
Same journal

Correction: Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.

International journal of clinical oncology·2026
Same journal

Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis.

International journal of clinical oncology·2026
Same journal

Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study.

International journal of clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Surgery and adjuvant chemotherapy.

Mitsuru Sasako1

  • 1Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. msasako@hyo-med.ac.jp

International Journal of Clinical Oncology
|June 17, 2008
PubMed
Summary
This summary is machine-generated.

Achieving good local control through radiotherapy or D2 surgery is crucial for curing gastric cancer. D2 surgery offers improved survival and safety compared to limited procedures, with extended surgery not recommended.

Related Experiment Videos

Last Updated: Jul 4, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastrointestinal Oncology

Background:

  • Gastric cancer treatment requires effective local control for curative outcomes.
  • Surgical approaches and adjuvant therapies are continuously evolving to improve patient survival and reduce morbidity.
  • Understanding the optimal surgical extent and the role of adjuvant treatments is critical for evidence-based clinical practice.

Purpose of the Study:

  • To evaluate the significance of local control in gastric cancer cure.
  • To compare the efficacy and safety of D2 surgery versus limited or more extended surgical procedures.
  • To review the current standards of care for adjuvant treatment in gastric cancer based on surgical approach and geographical region.

Main Methods:

  • Review of existing literature and clinical data on gastric cancer treatment modalities.
  • Analysis of survival rates and morbidity associated with different surgical techniques (limited surgery, D2 surgery, extended surgery).
  • Examination of the impact of various adjuvant treatments (chemotherapy, chemoradiotherapy, S-1 monotherapy) in conjunction with different surgical approaches.

Main Results:

  • Effective local control via radiotherapy or D2 surgery is essential for gastric cancer cure.
  • D2 surgery is safe, feasible in high-volume settings, and superior to limited surgery in terms of survival.
  • Surgery beyond D2 lymphadenectomy does not improve survival and increases morbidity, thus it is not recommended as prophylactic lymphadenectomy.
  • The efficacy of adjuvant treatment is contingent upon the type of surgery performed.

Conclusions:

  • D2 lymphadenectomy represents the standard surgical approach for gastric cancer, balancing efficacy and safety.
  • Adjuvant treatment strategies vary globally, with neoadjuvant plus post-operative triplet chemotherapy (Europe), postoperative adjuvant chemoradiotherapy (United States), and postoperative S-1 monotherapy (Japan) being current standards.
  • Optimizing local control and tailoring adjuvant therapies based on surgical extent are key to improving gastric cancer outcomes.